273 related articles for article (PubMed ID: 31614918)
1. Targeting Aberrant Sialylation to Treat Cancer.
Munkley J; Scott E
Medicines (Basel); 2019 Oct; 6(4):. PubMed ID: 31614918
[TBL] [Abstract][Full Text] [Related]
2. Aberrant Sialylation in Cancer: Therapeutic Opportunities.
Munkley J
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077781
[TBL] [Abstract][Full Text] [Related]
3. Targeting aberrant sialylation and fucosylation in prostate cancer cells using potent metabolic inhibitors.
Orozco-Moreno M; Visser EA; Hodgson K; Hipgrave Ederveen AL; Bastian K; Goode EA; Öztürk Ö; Pijnenborg JFA; Eerden N; Moons SJ; Rossing E; Wang N; de Haan N; Büll C; Boltje TJ; Munkley J
Glycobiology; 2023 Dec; 33(12):1155-1171. PubMed ID: 37847613
[TBL] [Abstract][Full Text] [Related]
4. Role of tumor cell sialylation in pancreatic cancer progression.
Marciel MP; Haldar B; Hwang J; Bhalerao N; Bellis SL
Adv Cancer Res; 2023; 157():123-155. PubMed ID: 36725107
[TBL] [Abstract][Full Text] [Related]
5. Insights into the Role of Sialylation in Cancer Metastasis, Immunity, and Therapeutic Opportunity.
Huang J; Huang J; Zhang G
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497322
[TBL] [Abstract][Full Text] [Related]
6. Sialic acid blockade inhibits the metastatic spread of prostate cancer to bone.
Hodgson K; Orozco-Moreno M; Goode EA; Fisher M; Garnham R; Beatson R; Turner H; Livermore K; Zhou Y; Wilson L; Visser EA; Pijnenborg JF; Eerden N; Moons SJ; Rossing E; Hysenaj G; Krishna R; Peng Z; Nangkana KP; Schmidt EN; Duxfield A; Dennis EP; Heer R; Lawson MA; Macauley M; Elliott DJ; Büll C; Scott E; Boltje TJ; Drake RR; Wang N; Munkley J
EBioMedicine; 2024 May; 104():105163. PubMed ID: 38772281
[TBL] [Abstract][Full Text] [Related]
7. I-branched carbohydrates as emerging effectors of malignant progression.
Dimitroff CJ
Proc Natl Acad Sci U S A; 2019 Jul; 116(28):13729-13737. PubMed ID: 31213534
[TBL] [Abstract][Full Text] [Related]
8. Lectin staining and Western blot data showing differential sialylation of nutrient-deprived cancer cells to sialic acid supplementation.
Badr HA; AlSadek DM; Mathew MP; Li CZ; Djansugurova LB; Yarema KJ; Ahmed H
Data Brief; 2015 Dec; 5():481-8. PubMed ID: 26629491
[TBL] [Abstract][Full Text] [Related]
9. Serum sialylation changes in cancer.
Zhang Z; Wuhrer M; Holst S
Glycoconj J; 2018 Apr; 35(2):139-160. PubMed ID: 29680984
[TBL] [Abstract][Full Text] [Related]
10. ST6GAL1: A key player in cancer.
Garnham R; Scott E; Livermore KE; Munkley J
Oncol Lett; 2019 Aug; 18(2):983-989. PubMed ID: 31423157
[TBL] [Abstract][Full Text] [Related]
11. Impact of Fc N-glycan sialylation on IgG structure.
Zhang Z; Shah B; Richardson J
MAbs; 2019; 11(8):1381-1390. PubMed ID: 31411531
[TBL] [Abstract][Full Text] [Related]
12. The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans.
Smith BAH; Bertozzi CR
Nat Rev Drug Discov; 2021 Mar; 20(3):217-243. PubMed ID: 33462432
[TBL] [Abstract][Full Text] [Related]
13. Cellular and Molecular Engineering of Glycan Sialylation in Heterologous Systems.
Hombu R; Neelamegham S; Park S
Molecules; 2021 Sep; 26(19):. PubMed ID: 34641494
[TBL] [Abstract][Full Text] [Related]
14. Sialic acid linkage-specific quantitative N-glycoproteomics using selective alkylamidation and multiplex TMT-labeling.
Yang H; Tian Z
Anal Chim Acta; 2022 Oct; 1230():340391. PubMed ID: 36192063
[TBL] [Abstract][Full Text] [Related]
15. Development of antimetastatic drugs by targeting tumor sialic acids.
Lu DY; Lu TR; Wu HY
Sci Pharm; 2012; 80(3):497-508. PubMed ID: 23008802
[TBL] [Abstract][Full Text] [Related]
16. Altered linkage pattern of N-glycan sialic acids in pseudomyxoma peritonei.
Nummela P; Heiskanen A; Kytölä S; Haglund C; Lepistö A; Satomaa T; Ristimäki A
Glycobiology; 2021 Apr; 31(3):211-222. PubMed ID: 33539510
[TBL] [Abstract][Full Text] [Related]
17. Implications of altered O-glycosylation in tumour immune evasion.
Itano N
J Biochem; 2019 May; 165(5):387-390. PubMed ID: 30649348
[TBL] [Abstract][Full Text] [Related]
18. Targeting sialylation to treat central nervous system diseases.
Lünemann JD; von Gunten S; Neumann H
Trends Pharmacol Sci; 2021 Dec; 42(12):998-1008. PubMed ID: 34607695
[TBL] [Abstract][Full Text] [Related]
19. Bifunctional unnatural sialic acids for dual metabolic labeling of cell-surface sialylated glycans.
Feng L; Hong S; Rong J; You Q; Dai P; Huang R; Tan Y; Hong W; Xie C; Zhao J; Chen X
J Am Chem Soc; 2013 Jun; 135(25):9244-7. PubMed ID: 23725545
[TBL] [Abstract][Full Text] [Related]
20. Regulation of sialic acid metabolism in cancer.
Filipsky F; Läubli H
Carbohydr Res; 2024 May; 539():109123. PubMed ID: 38669826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
